Zobrazeno 1 - 4
of 4
pro vyhledávání: '"May Zie Koh"'
Autor:
Mohammed Khaled Bin Break, Tan Yew Fung, May Zie Koh, Wan Yong Ho, Mohamed Ibrahim Mohamed Tahir, Omar Ashraf Elfar, Rahamat Unissa Syed, Weam M. A. Khojali, Turki Mubarak Alluhaibi, Bader Huwaimel, Christophe Wiart, Teng-Jin Khoo
Publikováno v:
Molecules, Vol 28, Iss 13, p 5009 (2023)
A series of novel macroacyclic Schiff base ligands and their Cu (II) complexes were synthesised via reacting dicarbonyls of varying chain lengths with S-methyl dithiocarbazate (SMDTC) and S-benzyl dithiocarbazate (SBDTC) followed by coordination with
Externí odkaz:
https://doaj.org/article/e75e33d31c7d4645a5dd533c859cec6a
Autor:
May Zie Koh, Wan Yong Ho, Swee Keong Yeap, Norlaily Mohd Ali, Lily Boo, Noorjahan Banu Alitheen
Publikováno v:
Pharmaceuticals, Vol 14, Iss 5, p 391 (2021)
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that promotes a higher risk of metastasis and cancer reoccurrence. Cisplatin is one of the potential anticancer drugs for treating TNBC. However, the occurrence of cisplatin
Externí odkaz:
https://doaj.org/article/c8cba86b85104984acc2530e6de88069
Autor:
Khoo, Mohammed Khaled Bin Break, Tan Yew Fung, May Zie Koh, Wan Yong Ho, Mohamed Ibrahim Mohamed Tahir, Omar Ashraf Elfar, Rahamat Unissa Syed, Weam M. A. Khojali, Turki Mubarak Alluhaibi, Bader Huwaimel, Christophe Wiart, Teng-Jin
Publikováno v:
Molecules; Volume 28; Issue 13; Pages: 5009
A series of novel macroacyclic Schiff base ligands and their Cu (II) complexes were synthesised via reacting dicarbonyls of varying chain lengths with S-methyl dithiocarbazate (SMDTC) and S-benzyl dithiocarbazate (SBDTC) followed by coordination with
Autor:
May Zie Koh, Wan Yong Ho, Swee Keong Yeap, Norlaily Mohd Ali, Chean Yeah Yong, Lily Boo, Noorjahan Banu Alitheen
Publikováno v:
Pathology, research and practice. 233
Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with higher risk of metastasis and cancer reoccurrence. Cisplatin is one of the potential anticancer drugs for treating TNBC, where its effectiveness remains challenged